专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2010101353A3 COMPOSITION CONTAINING HUMAN SERUM ALBUMIN-TIMP-2 FUSION PROTEIN AND ANTI-CANCER DRUG FOR PREVENTING OR TREATING CANCER 审中-公开
标题翻译：含有人血清白蛋白-TIP-2融合蛋白和抗癌药物的组合物用于预防或治疗癌症
公开(公告)号：WO2010101353A3
公开(公告)日：2010-11-11
申请号：PCT/KR2010000509
申请日：2010-01-28
申请人： BIOCUREPHARM CO LTD , LEE SANG MOK , HA JONG CHEON , LEE JUNG SIK , YANG JAE KYOON , HER SONG WOOK , KIM JEONG YOON
发明人： LEE SANG MOK , HA JONG CHEON , LEE JUNG SIK , YANG JAE KYOON , HER SONG WOOK , KIM JEONG YOON
IPC分类号： A61K38/38 , A61K31/337 , A61P35/00
CPC分类号： A61K31/337
摘要： The present invention relates to a composition containing human serum albumin-TIMP-2-fusion protein and an anti-cancer drug for preventing or treating cancer. A group in which the composition is administered remarkably suppresses vasculogenesis and reduces tumor volume comparing to a group in which either the human serum albumin-TIMP-2 fusion protein or the anti-cancer drug is administered singly. Thus, the composition can be used for preventing or treating cancer due to the strong effect of suppressing cancer growth.
摘要翻译：本发明涉及含有人血清白蛋白-TIMP-2-融合蛋白和抗癌药物的组合物，用于预防或治疗癌症。与其中单独施用人血清白蛋白-TIMP-2融合蛋白或抗癌药的组相比，施用组合物的组显着抑制血管发生并减少肿瘤体积。因此，由于抑制癌症生长的强大作用，组合物可用于预防或治疗癌症。

2. 发明申请

WO2010101353A9 COMPOSITION CONTAINING HUMAN SERUM ALBUMIN-TIMP-2 FUSION PROTEIN AND ANTI-CANCER DRUG FOR PREVENTING OR TREATING CANCER 审中-公开
标题翻译：含有人血清ALBUMIN-TIMP-2融合蛋白的组合物和用于预防或治疗癌症的抗癌药物
公开(公告)号：WO2010101353A9
公开(公告)日：2010-12-29
申请号：PCT/KR2010000509
申请日：2010-01-28
申请人： BIOCUREPHARM CO LTD , LEE SANG MOK , HA JONG CHEON , LEE JUNG SIK , YANG JAE KYOON , HER SONG WOOK , KIM JEONG YOON
发明人： LEE SANG MOK , HA JONG CHEON , LEE JUNG SIK , YANG JAE KYOON , HER SONG WOOK , KIM JEONG YOON
IPC分类号： A61K38/38 , A61K31/337 , A61P35/00
CPC分类号： A61K31/337
摘要： The present invention relates to a composition containing human serum albumin-TIMP-2-fusion protein and an anti-cancer drug for preventing or treating cancer. A group in which the composition is administered remarkably suppresses vasculogenesis and reduces tumor volume comparing to a group in which either the human serum albumin-TIMP-2 fusion protein or the anti-cancer drug is administered singly. Thus, the composition can be used for preventing or treating cancer due to the strong effect of suppressing cancer growth.
摘要翻译：本发明涉及含有人血清白蛋白-TMP-2-融合蛋白的组合物和用于预防或治疗癌症的抗癌药物。与其中单独施用人血清白蛋白-TMP-2融合蛋白或抗癌药物的组相比，组合物施用的组显着抑制血管发生并降低肿瘤体积。因此，由于抑制癌症生长的强烈作用，该组合物可用于预防或治疗癌症。

3. 发明申请

WO2009145573A2 RECOMBINANT ESCHERICHIA COLI FOR PRODUCING RECOMBINANT HUMAN VARIATION INTERFERON-BETA PROTEINS WHEREIN METHIONINE AT THE AMINO END IS REMOVED, AND PREPARATION METHOD THEREOF 审中-公开
标题翻译：用于生产在氨基末端的甲磺酸的重组人变异型干扰素蛋白质的重组蛋白质转移物及其制备方法
公开(公告)号：WO2009145573A2
公开(公告)日：2009-12-03
申请号：PCT/KR2009002835
申请日：2009-05-28
申请人： BIOCUREPHARM CO LTD , LEE SANG MOK , HA JONG CHEON , YANG JAE KYOON , LEE JUNG SIK , PARK BONG HWAN
发明人： LEE SANG MOK , HA JONG CHEON , YANG JAE KYOON , LEE JUNG SIK , PARK BONG HWAN
IPC分类号： C12N15/70
CPC分类号： C07K14/565
摘要： The present invention relates to recombinant Escherichia coli for producing recombinant human variation interferon-beta proteins wherein methionine at the amino end is removed, and to a preparation method thereof, and more particularly, to recombinant Escherichia coli for producing recombinant human variation interferon-beta proteins and to a preparation method thereof, wherein methionine at the amino end is removed by inserting recombinant human variation interferon-beta (rHu IFN-ßSer17, IFN-ß 1b) genes into pET21a(+) vector to produce recombinant expression vector pET21a(+)IFN-ßSer17, inserting methionine aminopeptidase genes into pSTV29 vector to produce recombinant expression vector pSTV29Map, and transforming the two recombinant expression vectors in a single colon bacillus (BL21(DE3)).
摘要翻译：本发明涉及用于产生重组人变异型干扰素-β蛋白的重组大肠杆菌，其中除去氨基末端的甲硫氨酸及其制备方法，更具体地，涉及用于产生重组人变异型干扰素-β蛋白质的重组大肠杆菌以及其制备方法，其中通过将重组人变异干扰素-β（rHu IFN-βSer17，IFN-β1b）基因插入pET21a（+）载体中来除去氨基末端的甲硫氨酸，以产生重组表达载体pET21a（+） IFN-βSer17将蛋氨酸氨基肽酶基因插入pSTV29载体中以产生重组表达载体pSTV29Map，并在单个大肠杆菌（BL21（DE3））中转化两种重组表达载体。

4. 发明申请

WO2009145573A9 RECOMBINANT ESCHERICHIA COLI FOR PRODUCING RECOMBINANT HUMAN VARIATION INTERFERON-BETA PROTEINS WHEREIN METHIONINE AT THE AMINO END IS REMOVED, AND PREPARATION METHOD THEREOF 审中-公开
标题翻译：重组大肠杆菌用于生产氨基末端甲硫氨酸的重组人类变异性干扰素β蛋白及其制备方法
公开(公告)号：WO2009145573A9
公开(公告)日：2010-05-20
申请号：PCT/KR2009002835
申请日：2009-05-28
申请人： BIOCUREPHARM CO LTD , LEE SANG MOK , HA JONG CHEON , YANG JAE KYOON , LEE JUNG SIK , PARK BONG HWAN
发明人： LEE SANG MOK , HA JONG CHEON , YANG JAE KYOON , LEE JUNG SIK , PARK BONG HWAN
IPC分类号： C12N15/70
CPC分类号： C07K14/565
摘要： The present invention relates to recombinant Escherichia coli for producing recombinant human variation interferon-beta proteins wherein methionine at the amino end is removed, and to a preparation method thereof, and more particularly, to recombinant Escherichia coli for producing recombinant human variation interferon-beta proteins and to a preparation method thereof, wherein methionine at the amino end is removed by inserting recombinant human variation interferon-beta (rHu IFN-ßSer17, IFN-ß 1b) genes into pET21a(+) vector to produce recombinant expression vector pET21a(+)IFN-ßSer17, inserting methionine aminopeptidase genes into pSTV29 vector to produce recombinant expression vector pSTV29Map, and transforming the two recombinant expression vectors in a single colon bacillus (BL21(DE3)).
摘要翻译：本发明涉及重组大肠杆菌及其制备方法，特别涉及用于生产重组人类变异干扰素-β蛋白的重组大肠杆菌，所述重组大肠杆菌用于产生其中氨基末端的甲硫氨酸被去除的重组人类变异干扰素-β蛋白及其制备方法，其中通过将重组人变异干扰素-β（rHu IFN-βSer17，IFN-β1b）基因插入pET21a（+）载体中以去除氨基末端的甲硫氨酸以产生重组表达载体pET21a（+） IFN-βSer17，将甲硫氨酸氨肽酶基因插入pSTV29载体中，产生重组表达载体pSTV29Map，并将两种重组表达载体转化到单一结肠杆菌中（BL21（DE3））。

5. 发明申请

WO2011132966A3 TRANSDERMAL ABSORPTION PREPARATION 审中-公开
标题翻译：超吸收制剂
公开(公告)号：WO2011132966A3
公开(公告)日：2012-04-12
申请号：PCT/KR2011002887
申请日：2011-04-21
申请人： ICURE PHARMACEUTICAL INC , CHOI YOUNG KWEON , KIM JUNG JU , KIM SEONG SU , LEE JUNG SIK , PARK SEONG MIN
发明人： CHOI YOUNG KWEON , KIM JUNG JU , KIM SEONG SU , LEE JUNG SIK , PARK SEONG MIN
IPC分类号： A61K9/70 , A61K31/404 , A61P25/00
CPC分类号： A61K9/7061 , A61K9/7053 , A61K9/7076 , A61K31/4045
摘要： The present invention relates to a transdermal absorption preparation. The transdermal absorption preparation of the present invention comprises a drug-containing adhesive layer, a drug-protective layer and a release layer, wherein the drug-containing layer contains ropinirole or a salt thereof, rubber, an adhesion-imparting resin, an antioxidant, and a transdermal absorption promoter. Also, the present invention provides a transdermal absorption preparation comprising a drug-containing adhesive layer, a drug-protective layer and a release layer, wherein the drug-containing layer contains ropinirole or a salt thereof, acrylic rubber, an anti-crystallization agent, and a transdermal absorption promoter. When the transdermal absorption preparation of the present invention is used for the treatment of Parkinson's disease or restless leg syndrome, no side effect due to an increase in the initial concentration in blood occurs and the skin penetration effect of the drug is excellent.
摘要翻译：本发明涉及透皮吸收制剂。本发明的透皮吸收制剂包含含药物的粘合剂层，药物保护层和剥离层，其中药物含有层含有罗哌尼罗或其盐，橡胶，赋形树脂，抗氧化剂，和透皮吸收促进剂。另外，本发明提供了含有药物的粘合剂层，药物保护层和剥离层的透皮吸收制剂，其中药物含有层含有罗哌尼罗或其盐，丙烯酸橡胶，抗结晶剂，和透皮吸收促进剂。当本发明的经皮吸收制剂用于治疗帕金森病或不宁腿综合征时，由于血液中初始浓度的增加而引起副作用，药物的皮肤渗透作用优异。

6. 发明申请

WO2009120002A3 PERCUTANEOUS PREPARATION CONTAINING DONEPEZIL AS ACTIVE INGREDIENT FOR TREATMENT OF DEMENTIA 审中-公开
标题翻译：含有多西他赛作为主要成分用于治疗DEMENTIA的PERCUTANEOUS制剂
公开(公告)号：WO2009120002A3
公开(公告)日：2009-12-23
申请号：PCT/KR2009001472
申请日：2009-03-23
申请人： ICURE PHARMACEUTICAL INC , CHOI YOUNG KWEON , LEE JUNG SIK , KIM SUNG SOO , GU HYE RAN
发明人： CHOI YOUNG KWEON , LEE JUNG SIK , KIM SUNG SOO , GU HYE RAN
IPC分类号： A61K31/445
CPC分类号： A61K31/445 , A61K9/7053
摘要： The present invention relates to a percutaneous preparation containing donepezil as an active ingredient for treatment of dementia. More specifically, the percutaneous preparation comprising donepezil as the active ingredient consists of a matrix layer containing drugs, a support layer for protecting the drugs, and a release layer. The matrix layer containing drugs comprises: donepezil or pharmaceutically acceptable salts thereof as the active ingredient; polyethylene vinyl acetate adhesives including rosin ester resin as a polymer substrate; and a penetration enhancer mixture of at least two kinds selected from the group consisting of pyrrolidone derivatives, C8-18 aliphatic derivatives, triacetin and triethyl citrate. The disclosed percutaneous preparation can increase dementia patient administration compliance and minimize side effects when compared with an oral preparation. Additionally, the percutaneous preparation is easily applied to skin and can release the drugs sustainably for a long time. Also, due to high skin-penetration properties, the preparation can replace conventional oral preparations for treatment of dementia.
摘要翻译：本发明涉及含有多奈哌齐作为治疗痴呆的活性成分的经皮制剂。更具体地，包含多奈哌齐作为活性成分的经皮制剂由含有药物的基质层，用于保护药物的支持层和释放层组成。含有药物的基质层包括：多奈哌齐或其药学上可接受的盐作为活性成分; 聚乙烯乙酸乙烯酯粘合剂，包括松香酯树脂作为聚合物基材; 以及选自吡咯烷酮衍生物，C 8-18脂族衍生物，三醋精和柠檬酸三乙酯中的至少两种的渗透促进剂混合物。当与口服制剂相比时，所公开的经皮制剂可以增加痴呆患者施用顺应性和最小化副作用。此外，经皮制剂容易应用于皮肤，并且可长期释放药物。此外，由于高的皮肤渗透性，该制剂可以替代用于治疗痴呆的常规口服制剂。

7. 发明申请

WO2012124966A2 FENTANYL TRANSDERMAL PATCH 审中-公开
公开(公告)号：WO2012124966A2
公开(公告)日：2012-09-20
申请号：PCT/KR2012001809
申请日：2012-03-13
申请人： ICURE , CHOI YOUNG KWEN , KIM JUNG JU , LEE JUNG SIK , KIM SUNG SOO
发明人： CHOI YOUNG KWEN , KIM JUNG JU , LEE JUNG SIK , KIM SUNG SOO
IPC分类号： A61K9/70 , A61F13/02 , A61K31/445 , A61L15/44
CPC分类号： A61K9/7076 , A61F13/02 , A61F13/0206 , A61F13/0246 , A61F13/0253 , A61F13/0256 , A61K9/7053 , A61K31/4468 , A61K31/454 , A61L15/44 , A61L15/58 , A61L2300/402 , A61M35/00 , F04C2270/0421 , C08L33/08
摘要： Provided is a fentanyl transdermal patch comprising an acrylic-rubber hybrid having a drug / adhesive layer. The fentanyl transdermal patch can maintain constant fentanyl skin permeability for three days by maintaining close contact with skin such that desorption, release by moisture and sweat, and skin stimulation are all improved.
摘要翻译：提供包含具有药物/粘合剂层的丙烯酸 - 橡胶混合物的芬太尼透皮贴剂。芬太尼透皮贴剂通过保持与皮肤的紧密接触使得芬太尼皮肤渗透性保持恒定三天，从而解吸，通过水分和汗液释放以及皮肤刺激均得到改善。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式